$ 350.0
Quantity: 10 MG
In stock
Description
Product name: Degarelix
Catalog#: 1224011
Synonyms: uglypeptide1,
CAS NO.: 214766-78-6
Sequence: Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2
M.W: 1632.26
M.F.: C82H103ClN18O16
Purity: 95% by HPLC
Counter ion: Trifluoacetate
Format: Lyophilized powder
Description: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. FDA approved on December 24, 2008. Degarelix has been shown in animal studies to antagonize GnRH receptors in the pituitary gland, resulting in a significant reduction in circulating LH and a subsequent decrease in the synthesis of testosterone. Pharmacokinetic analysis suggests that upon subcutaneous administration, degarelix forms a gel depot, from which the drug then distributes to the rest of the body in a first-order manner.
Uniprot ID: 16136245
Usage: For Scientific Research Use Only, Not for Human Use.
